Zoetis Inc. (NYSE:ZTS) – Stock analysts at William Blair boosted their FY2017 earnings estimates for shares of Zoetis in a report released on Wednesday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $2.34 per share for the year, up from their previous forecast of $2.31. William Blair also issued estimates for Zoetis’ Q4 2017 earnings at $0.66 EPS, FY2018 earnings at $2.64 EPS, FY2019 earnings at $2.92 EPS and FY2020 earnings at $3.23 EPS.
Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 64.16%. Zoetis’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS.
A number of other analysts also recently issued reports on ZTS. BMO Capital Markets restated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Thursday, May 4th. Jefferies Group LLC raised their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a report on Wednesday, May 10th. Credit Suisse Group raised their price objective on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Finally, CL King initiated coverage on shares of Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus target price of $64.78.
Shares of Zoetis (ZTS) opened at 60.81 on Thursday. The company’s 50 day moving average is $62.40 and its 200 day moving average is $57.94. Zoetis has a one year low of $46.86 and a one year high of $63.85. The company has a market cap of $29.85 billion, a P/E ratio of 35.35 and a beta of 1.02.
A number of large investors have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America raised its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Sii Investments Inc. WI raised its stake in shares of Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock valued at $383,000 after buying an additional 23 shares during the last quarter. Argent Trust Co raised its stake in shares of Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock valued at $221,000 after buying an additional 32 shares during the last quarter. Ironwood Investment Management LLC raised its stake in shares of Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock valued at $429,000 after buying an additional 48 shares during the last quarter. Finally, CENTRAL TRUST Co raised its stake in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares during the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares in the company, valued at $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.31% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be given a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 annualized dividend and a yield of 0.69%. Zoetis’s payout ratio is presently 23.73%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.